Long non-coding RNA ENTPD1-AS1 exerts pro-oncogenic activities in colorectal cancer by acting as a competing endogenous RNA for microRNA-432-5p to increase HDGF expression

H. Deng; Q. Li; ZH. Qi; XK. Bi; QY Huang

doi:10.54517/jbrha4484

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

Long non-coding RNA ENTPD1-AS1 exerts pro-oncogenic activities in colorectal cancer by acting as a competing endogenous RNA for microRNA-432-5p to increase HDGF expression

H. Deng, Q. Li, ZH. Qi, XK. Bi, QY Huang

Article ID: 4484
Vol 35, Issue 6, 2021

DOI: https://doi.org/10.54517/jbrha4484

Received: 8 January 2022; Accepted: 8 January 2022; Available online: 8 January 2022; Issue release: 8 January 2022

Abstract

ENTPD1 antisense RNA 1 (ENTPD1-AS1), a long non-coding RNA, has been comprehensively studiedin glioblastoma multiforme. This study aimed to measure ENTPD1-AS1 expression in patients withcolorectal cancer (CRC) and identify its function in the behavior of CRC cells. The expression of ENTPD1-AS1 was measured in a panel of tissue specimens obtained from CRC patients via quantitative real-timepolymerase chain reaction. Proliferation, migration, and invasion of CRC cells were evaluated using CellCounting Kit-8, Transwell cell migration, and invasion assays. Moreover, tumor xenografts were establishedto evaluate the growth of CRC cells in vivo, and bioinformatics analysis was performed to identify putativecomplementary miRNAs that interact with ENTPD1-AS1, which was further corroborated in a seriesof mechanistic studies. We found that ENTPD1-AS1 was overexpressed in CRC based on our samplecohort’s Cancer Genome Atlas database. Interference of ENTPD1-AS1 impeded CRC cell proliferation.In addition, in vitro migration and invasion as well as in vivo tumor growth were inhibited after ENTPD1-AS1 knockdown. Mechanistically, ENTPD1-AS1 predominantly functioned as a competing endogenousRNA to sponge microRNA-432-5p (miR-432-5p), resulting in the upregulation of hepatoma-derivedgrowth factor (HDGF) expression in CRC cells. Finally, rescue function tests revealed that miR-432-5pinhibition or HDGF restoration could counteract the inhibitory effects of ENTPD1-AS1 knockdown inCRC cells. Overall, ENTPD1-AS1 may increase HDGF expression in CRC cells by sequestering miR-432-5p, thereby boosting oncogenicity. Thus, the ENTPD1-AS1/miR-432-5p/HDGF regulatory pathway mayprovide a theoretical basis for the identification of novel treatment strategies for CRC

Keywords

ENTPD1 antisense RNA 1;ceRNA;molecular sponge;microRNA-432-5p;hepatoma-derived growth factor

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...